News

playbook.jpg

ACR 2017 Playbook

Jack Cush, MD

The annual ACR/ARHP meeting, which begins today, Sunday November 5th, is for many the premier meeting in rheumatology. The good news is that RheumNow and its expanded faculty will cover the meeting today and each day until Thursday. I haven’t missed an ACR meeting since 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 15,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, Costco gone wild and a sold-out Margaritaville concert. Here's my ACR Playbook.

gout.MTP_.jpg

Ironwood Featured Presentations

Jack Cush, MD

Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017.

wkinreview1_13.jpg

The RheumNow Week in Review - 3 November 2017

Jack Cush, MD

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. Hear about death and risk of lupus, tight control in Crohn's, risk of knee OA, new diagnostic tool for PMR, keeping infections low with biologics and new shingles vaccine, and infection concerns for San Diego.

T2T.Crohns.png

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Jack Cush, MD

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.

pills-14550__180_0.jpg

NSAID and Opioid Adverse Event Reports from MedWatch

Jack Cush, MD

One-third of adults in the USA experience chronic pain and take prescription nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids.

digit.ulcer_.jpg

Tocilizumab Benefits Persist in SSc

RheumNow

Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.

tick.jpg

High Volume Lyme Disease Reporting in Low Incidence Arkansas

Jack Cush, MD

Even though Arkansas lies on the edge of the geographic range of the principal Lyme disease tick vector, Ixodes scapularis, the risk for Lyme infection is low, and no confirmed Lyme disease cases were reported in Arkansas during 2008–2014 (1)

myositis.jpg

New EULAR/ACR Classification Criteria for Adult and Juvenile Myositis

Jack Cush, MD

The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) have developed classification criteria for idiopathic inflammatory myopathies (IIM) based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% ad

lupus_0.jpg

Death Rates from Lupus Remain Disproportionately High

Jack Cush, MD

The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates. 

Nets.jpg

Necroptosis Drives Netosis and ANCA-Associated Vasculitis

Jack Cush, MD

PNAS reports that ANCA induced neutrophil activation, generation of neutrophil extracellular traps (NETS), and vasculitis are regulated by necroptosis. Using inhibitors of necroptosis-inducing kinases they were able to prevent ANCA associated vasculitis (AAV) in animal models. 

placenta.jpg

CRIB Study Shows No Transplacental Transfer of Certolizumab

Jack Cush, MD

Mariette and colleagues have reported on the prospective pharmacokinetic study of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants at the time of birith.

Vaccine2.jpg (keep)

CDC Endorses New Shingles Vaccine Over Zostavax

Jack Cush, MD

The  U.S. Centers for Disease Control (CDC) announced on 25 October they endorsed the use of the new GSK shingles vaccine (Shingrix) over the currently available live-virus vaccine (Zostavax) from Merck. 

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×